Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors
Matthew Brudner equal contributor, Marshall Karpel equal contributor, Calli Lear, Li Chen, L. Michael Yantosca, Corinne Scully, [Affiliation: Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, United States of America] Ashish Sarraju, Anna Sokolovska, M. Reza Zariffard, Damon P. Eisen, Bruce A. Mungall, Darrell N. Kotton, Amel Omari, I-Chueh Huang, Michael Farzan, Kazue Takahashi, Lynda Stuart, Gregory L. Stahl, Alan B. Ezekowitz, Gregory T. Spear, Gene G. Olinger, Emmett V. Schmidt mail, Ian C. Michelow mail
Published: April 02, 2013 DOI: 10.1371/journal.pone.0060838
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
Larry Zeitlina,1, James Pettittb, Corinne Scully b, Natasha Bohorovaa, Do Kima, Michael Paulya, Andrew Hiatta, Long Ngoc, Herta Steinkellnerd, Kevin J. Whaleya, and Gene G. Olingerb Author Affiliations
aMapp Biopharmaceutical, San Diego, CA 92121; bDepartment of Virology, US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702; cDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215; and dDepartment of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria Edited* by Charles J. Arntzen, Arizona State University, Tempe, AZ, and approved July 28, 2011 (received for review May 25, 2011)